Liège, Belgium, 18 June 2020 20:30 CEST – Mithra Pharmaceuticals SA (the “Company” or “Mithra”), a company specialized in Women’s Health (Euronext Brussels: MITRA), announces today that it successfully raised an amount of EUR 65.0 million in gross proceeds by means of a private placement via an accelerated bookbuild offering of 3,421,052 new shares (being approximately 8.74% of the Company’s outstanding shares) at an issue price of EUR 19.00 per share (the “Private Placement“).
François Fornieri, CEO Mithra Women’s Health, commented: “We are very pleased to have completed this transaction with an oversubscribed book of Tier 1 and specialist healthcare investors, and a competitive pricing. This private placement represents a key step in our funding strategy, carrying us through to commercialization of for our next-generation contraceptive Estelle®, as well as the further development of Donesta®, our novel product candidate for menopause.“